Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$91.54 USD
+0.60 (0.66%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $91.55 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -239.24 | -187.13 | -130.40 | -102.90 | -68.35 |
Depreciation/Amortization & Depletion | 9.41 | 7.05 | 2.23 | 0.86 | 0.69 |
Net Change from Assets/Liabilities | -28.24 | 22.55 | -0.86 | 0.42 | 15.17 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 112.99 | 41.02 | 20.80 | 23.16 | 6.12 |
Net Cash From Operating Activities | -145.08 | -116.51 | -108.23 | -78.46 | -46.38 |
Property & Equipment | -0.58 | -0.70 | -0.31 | -0.05 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -53.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.58 | -53.70 | -0.31 | -0.05 | -0.02 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 271.17 | 243.04 | 11.61 | 15.18 | 239.63 |
Issuance (Repayment) of Debt | 85.00 | 45.00 | 0.00 | 28.34 | 12.76 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -25.16 | -3.46 | -0.49 | -1.10 | 0.00 |
Net Cash from Financing Activities | 331.01 | 284.58 | 11.13 | 42.41 | 252.39 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 185.35 | 114.37 | -97.40 | -36.09 | 206.00 |
Cash at Beginning of Period | 200.84 | 86.47 | 183.88 | 219.97 | 13.97 |
Cash at End of Period | 386.19 | 200.84 | 86.47 | 183.88 | 219.97 |
Diluted Net EPS | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 |
Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -147.70 | -68.36 | -239.24 | -140.59 | -78.39 |
Depreciation/Amortization & Depletion | 5.41 | 2.45 | 9.41 | 7.21 | 5.62 |
Net Change from Assets/Liabilities | 16.02 | -6.70 | -28.24 | -31.88 | -23.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 42.69 | 19.14 | 112.99 | 50.53 | 34.76 |
Net Cash From Operating Activities | -83.58 | -53.47 | -145.08 | -114.72 | -61.17 |
Property & Equipment | -0.15 | -0.10 | -0.58 | -0.58 | -0.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.15 | -0.10 | -0.58 | -0.58 | -0.20 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 20.16 | 2.50 | 271.17 | 270.02 | 231.96 |
Issuance (Repayment) of Debt | 0.00 | -0.16 | 85.00 | 85.00 | 85.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -6.97 | -3.53 | -25.16 | -24.01 | -19.31 |
Net Cash from Financing Activities | 13.19 | -1.19 | 331.01 | 331.02 | 297.65 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -70.54 | -54.75 | 185.35 | 215.72 | 236.27 |
Cash at Beginning of Period | 386.19 | 386.19 | 200.84 | 200.84 | 200.84 |
Cash at End of Period | 315.66 | 331.44 | 386.19 | 416.56 | 437.11 |
Diluted Net EPS | -1.67 | -1.44 | -2.15 | -1.32 | -1.54 |